Original language | English |
---|---|
Pages (from-to) | 1645-1653 |
Number of pages | 9 |
Journal | Lancet |
Volume | 390 |
Issue number | 10103 |
DOIs | |
Publication status | Published - 7 Oct 2017 |
Keywords
- BRAIN-TUMOR GROUP
- LOW-GRADE GLIOMA
- EUROPEAN ORGANIZATION
- OLIGODENDROGLIAL TUMORS
- IDH2 MUTATIONS
- III TRIAL
- PROCARBAZINE
- VINCRISTINE
- GLIOBLASTOMA
- CHEMOTHERAPY
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma : a phase 3, randomised, open-label intergroup study. / van den Bent, Martin J.; Baumert, Brigitta; Erridge, Sara C.; Vogelbaum, Michael A.; Nowak, Anna K.; Sanson, Marc; Brandes, Alba Ariela; Clement, Paul M.; Baurain, Jean Francais; Mason, Warren P.; Wheeler, Helen; Chinot, Olivier L.; Gill, Sanjeev; Griffin, Matthew; Brachman, David G.; Taal, Walter; Ruda, Roberta; Weller, Michael; McBain, Catherine; Reijneveld, Jaap; Enting, Roelien H.; Weber, Damien C.; Lesimple, Thierry; Clenton, Susan; Gijtenbeek, Anja; Pascoe, Sarah; Herrlinger, Ulrich; Hau, Peter; Dhermain, Frederic; van Heuvel, Irene; Stupp, Roger; Aldape, Ken; Jenkins, Robert B.; Dubbink, Hendrikus Jan; Dinjens, Winand N. M.; Wesseling, Pieter; Nuyens, Sarah; Golfinopoulos, Vassilis; Gorlia, Thierry; Wick, Wolfgang; Kros, Johan M.
In: Lancet, Vol. 390, No. 10103, 07.10.2017, p. 1645-1653.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma
T2 - a phase 3, randomised, open-label intergroup study
AU - van den Bent, Martin J.
AU - Baumert, Brigitta
AU - Erridge, Sara C.
AU - Vogelbaum, Michael A.
AU - Nowak, Anna K.
AU - Sanson, Marc
AU - Brandes, Alba Ariela
AU - Clement, Paul M.
AU - Baurain, Jean Francais
AU - Mason, Warren P.
AU - Wheeler, Helen
AU - Chinot, Olivier L.
AU - Gill, Sanjeev
AU - Griffin, Matthew
AU - Brachman, David G.
AU - Taal, Walter
AU - Ruda, Roberta
AU - Weller, Michael
AU - McBain, Catherine
AU - Reijneveld, Jaap
AU - Enting, Roelien H.
AU - Weber, Damien C.
AU - Lesimple, Thierry
AU - Clenton, Susan
AU - Gijtenbeek, Anja
AU - Pascoe, Sarah
AU - Herrlinger, Ulrich
AU - Hau, Peter
AU - Dhermain, Frederic
AU - van Heuvel, Irene
AU - Stupp, Roger
AU - Aldape, Ken
AU - Jenkins, Robert B.
AU - Dubbink, Hendrikus Jan
AU - Dinjens, Winand N. M.
AU - Wesseling, Pieter
AU - Nuyens, Sarah
AU - Golfinopoulos, Vassilis
AU - Gorlia, Thierry
AU - Wick, Wolfgang
AU - Kros, Johan M.
PY - 2017/10/7
Y1 - 2017/10/7
KW - BRAIN-TUMOR GROUP
KW - LOW-GRADE GLIOMA
KW - EUROPEAN ORGANIZATION
KW - OLIGODENDROGLIAL TUMORS
KW - IDH2 MUTATIONS
KW - III TRIAL
KW - PROCARBAZINE
KW - VINCRISTINE
KW - GLIOBLASTOMA
KW - CHEMOTHERAPY
U2 - 10.1016/S0140-6736(17)31442-3
DO - 10.1016/S0140-6736(17)31442-3
M3 - Article
VL - 390
SP - 1645
EP - 1653
JO - Lancet
JF - Lancet
SN - 0140-6736
IS - 10103
ER -